Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis-Reference-Cited by-同舟云学术

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Published:2018-02 Issue:2 Volume:19 Page:229-239
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Beaver Julia A,Hazarika Maitreyee,Mulkey Flora,Mushti Sirisha,Chen Huanyu,He Kun,Sridhara Rajeshwari,Goldberg Kirsten B,Chuk Meredith K,Chi Dow-Chung,Chang Jennie,Barone Amy,Balasubramaniam Sanjeeve,Blumenthal Gideon M,Keegan Patricia,Pazdur Richard,Theoret Marc R

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

2. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab;Hodi;J Clin Oncol,2016

3. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria;Wolchok;Clin Cancer Res,2009

4. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements;Nishino;Clin Cancer Res,2013

5. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study;O'Day;Ann Oncol,2010

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention;Heliyon;2024-09

3. Optimized Bionic Drug-Delivery-Inducing Immunogenic Cell Death and cGAS-STING Pathway Activation for Enhanced Photodynamic-Chemotherapy-Driven Immunotherapy in Prostate Cancer;ACS Applied Materials & Interfaces;2024-08-09

4. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation;Critical Reviews in Oncology/Hematology;2024-08

5. Tumor-specific high-valence bismuth(V) nanoplatform potentiates cancer immunotherapy with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation;2024-07-15